Singapore Aquatics bolsters coaching team with Japanese Masataka Ishimatsu's expertise
The announcement by the Singapore Aquatics (SAQ) on May 29 coincides with its National Training Centre's 10th anniversary this year, as the national sports association charts a bold course for the future with a strategic expansion of both its coaching and sport science teams.
'I'm excited to be part of the team at Singapore Aquatics, especially as the National Training Centre enters this new chapter. I have seen firsthand how committed teams can make a big impact on the world stage,' said SAQ's co-lead coach Ishimatsu.
Ishimatsu, a key figure in Japan's Olympic coaching setup from 2017 to 2025, will be supporting Singapore's national swimming head coach, Gary Tan, alongside current lead coaches Alexander Mordvincev and Gustavo Schirru.
'The recent growth of our National Training Centre marks a pivotal moment in our pursuit of sporting excellence. By blending experienced international coaches with promising local talents, we are building a high-performance system geared for both immediate success and long-term sustainability. The addition of Masataka Ishimatsu strengthens our depth in middle-distance events, complementing our existing strengths,' expressed Gary Tan, SAQ's national head coach. Singapore Aquatic's national training centre co-lead Singapore Aquatics – Masataka Ishimatsu and national swimming head coach Gary Tan. (Photo credit: Singapore Aquatics)
Ishimatsu brings extensive international experience, having trained some of Japan's most decorated swimmers, including two-time Olympic gold medalist Yui Ohashi, two-time Olympic medalist Ryosuke Irie, and Akihiro Yamaguchi, a former world record holder in the 200m breaststroke.
Beyond his coaching credentials, Ishimatsu has played a key role in developing national training camps and technical planning structures for Japan's elite squads and is highly regarded within Japan's coaching community as a rising leader in high-performance swimming coaching.
'My goal is to contribute not just in the pool but also by sharing technical knowledge and coaching culture that supports long-term success. I look forward to working with the athletes and staff to build something special together,' added the 38-year-old Japanese swimming coach.
SAQ also shared that they remain focused on preparing a strong and competitive team for the LA 2028 Olympics, and they are working to deliver world-class performance through enhanced coaching and sport science capabilities. Ex-national swimmers nurturing the next generation
Former national swimmer Zach Ong will join SAQ as coach of the Emerging Talents Programme, where he will lead efforts to shape and develop Singapore's next generation of youth swimmers. Meanwhile, Donovan Lee will step into his new role as sports science executive. The sports science team will also welcome Koh Chiya as a full-time high-performance sports scientist. See also Golden gift from Shanti Pereira and Remy Ong to National Museum
SAQ's national swimming head coach Tan also pointed out that as they prepare for the 2028 Olympics, they are 'dedicated to nurturing a strong pipeline of junior athletes and cultivating a strong coaching workforce rooted in local expertise, setting the foundation for our development into a world-class aquatics nation.'
These appointments underscore SAQ's long-term commitment to nurturing local talent, with Ong and Lee's transition from national athletes to technical and coaching roles reflecting a purpose-driven pipeline that invests in individuals with lived experience in high-performance sport. Former national swimmer Donovan Lee will join Singapore Aquatics' sport science set-up. (Photo credit: Singapore Aquatics)
'As we mark 10 years of the National Training Centre, we are not only celebrating a significant milestone but also charting the next phase of our journey. Moving forward, we are placing greater emphasis on developing a robust pipeline of coaching talent,' said Associate Professor Kenneth Goh, President of SAQ.
Goh shared that their goal is to build a sustainable, high-performance ecosystem anchored in home-grown talent. This includes providing meaningful opportunities to the local coaching community through educational workshops and on-deck mentorship from both local and international experts.
'This long-term investment in people and systems will strengthen Singapore's competitiveness in aquatics across all levels—from junior development right through to the Olympic stage,' added Goh.
Apart from the 2028 Olympics, SAQ also highlighted its commitment to building a broad talent pipeline that will develop more athletes ready to compete in the 2026 Asian Games, as well as the 2027 and 2029 SEA Games.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
2 hours ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
CNA
5 hours ago
- CNA
Singapore's hunt for new national football coach down to five names
Singapore's hunt for a national football coach intensifies as a few candidates, including former Tottenham Hotspur assistant coach Nick Montgomery, are in town for interviews to snag the top job. CNA understands the shortlist is down to five, cut from 10 just a week ago. The new man will replace Tsutomu Ogura, who quit last month for personal reasons. Aslam Shah reports.
CNA
5 hours ago
- CNA
Asia First - Wed 13 Aug 2025
02:27:30 Min From the opening bell across markets in Southeast Asia and China, to the biggest business interviews and top financial stories, tune in to Asia First to kick-start your business day.
